Primary Central Nervous System Lymphoma
Conditions
Interventions
experimental group:Rituximab combined with thiotepa, dexamethasone, and ibrutinib or pomalidomide
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-69 years old; 2. Patients diagnosed with primary central nervous system lymphoma by pathological histological; 3. Ready to receive induction therapy with no previous history of chemotherapy or radiotherapy; 4. ECOG score of 0-2 points; 5. Expected survival >=3 months; 6. Normal function of major organs, laboratory test results meet the following criteria: a. Alanine aminotransferase (ALT) =90 g/L, neutrophil >=1.5×109/L, platelet >=100×109/L 7. No other serious diseases; 8. Volunteer to participate in this clinical trial, understand the study procedures, and be able to sign the informed consent form in writing.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Individuals allergic to the study drug or its metabolites; 3.Uncontrolled active infections; 4.Any concomitant disease, as determined by the investigator, that poses a serious risk to patient safety or may interfere with the completion of the study; 5.Other conditions, as determined by the investigator, that make participation in the study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response rate;Overall survival;Progression-free survival;Adverse events; | — |
Countries
China
Contacts
Public ContactNi Xun
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed